drugset / Trial / NCT00694785
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
RandomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the effect of ARC1779, a therapeutic oligonucleotide ("aptamer") in patients with Type2B von Willebrand Disease.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EGAPTIVON PEGOL | Aptamer | 1.3 mg/kg | Intravenous |
| Subject | EGAPTIVON PEGOL | Aptamer | 1.7 mg/kg | Intravenous |
| Subject | EGAPTIVON PEGOL | Aptamer | 3 mg/kg | Intravenous |
| Subject | EGAPTIVON PEGOL | Aptamer | 3.8 mg/kg | Intravenous |